Moderna Inc. (MRNA:NSD) Analysts are bearish with a Underperform rating

STA Research
by: STA Research
Moderna Inc

Based on the Moderna stock forecast from 7 analysts, the average analyst MRNA stock price target is USD 147.62 over the next 12 months. Moderna Inc’s average analyst rating is Underperform. Stock Target Advisor’s own Moderna stock forecast is Bullish, which is based on 10 positive signals and 4 negative signals. At the last closing, MRNA stock price was USD 186.49MRNA stock price has changed by +28.47% over the past week, +36.54% over the past month and -55.50% over the last year.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

 

What we like:

High market capitalization:

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns:

Moderna stock price has performed well, on a risk adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity:

Moderna stock price history shows better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization:

Moderna stock price history shows better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets:

Moderna stock price history shows better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow:

Moderna stock forecast has displayed positive total cash flow in the most recent four quarters.

Positive free cash flow:

Moderna stock forecast has displayed positive total free cash flow in the most recent four quarters.

Superior Earnings Growth:

Moderna stock price history has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth:

Moderna stock price history has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio:

MRNA stock price is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

 

What we don’t like:

High volatility:

Moderna stock price history shows that the total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value:

MRNA stock price is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis:

MRNA stock price is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis:

MRNA stock price is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Disclaimer

Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.